Ester Active Ingredients TRIZ Cases

Alpha-GEE treats osteoarthritis by stabilizing mitochondrial permeability and lowering inflammatory markers without the toxic side effects of NSAIDs.

Oral tricaprin targets triglyceride deposits to regress refractory atherosclerosis and improve blood flow when LDL-lowering alone falls short.

Targeting mitochondrial pyruvate transport helps suppress TKI-resistant CML stem cells and improve remission with BCR-ABL inhibitor combinations.

Heart failure therapy struggles with declining cardiac output and fibrosis; this ester-containing compound improves function and limits remodeling.

Lipophilic semiochemicals disperse in water without ethoxydiglycol, supporting long-shelf-life topical formulations for animals and humans.

Short-chain fatty acids activate endocrine pathways to lower blood pressure while minimizing side effects linked to conventional agents.

Small molecules bind specific KCNQ channel domains to resolve conflicting structural models and treat epilepsy, deafness, and arrhythmias.

Ascorbate inhibits osteoblastic differentiation in vascular smooth muscle cells, resolving statin-induced calcification risks.

Selenium nanoparticles conjugated with sulforaphane reduce systemic toxicity while enhancing selective cytotoxicity against breast cancer cells.

Statins inhibit endothelial-to-mesenchymal transition, reducing portal vein wall thickening and treating thrombosis.

Trimebutine derivatives selectively target cancer stem cells to suppress tumor recurrence, metastasis, and progression.

Daily administration of 4g EPA and DHA ethyl esters reduces arrhythmia-related deaths and hospitalizations over 3.5 years.

Leonurine lowers lactate dehydrogenase release while minimizing toxic side effects, improving cardiac function in heart failure treatment.

Oral ketone ester supplements induce metabolic ketosis to elevate blood ketone levels in patients.

Combines statins with purified omega-3 fatty acids to stabilize vulnerable plaques, addressing limitations in existing lipid-regulating medications.

Composition combining exogenous ketone bodies, NAD modulators, and methyl donors prevents depletion side effects while elevating energy metabolism.

Segments drug interaction profiles using in silico modeling to predict metabolic conflicts between PPAR agonists and P38 inhibitors before clinical trials.

Removing hydroxyl and carboxyl groups from the polymer matrix prevents rivastigmine oxidation without adding antioxidants.

Integrated silicone gel adhesive and polymer layer reduces skin irritation while maintaining mechanical stability during release liner removal.

A pharmaceutical capsule combines ethyl eicosapentaenoate with atorvastatin to deliver sustained release.

A surfactant mixture disrupts bacterial biofilms to release embedded pathogens for subsequent treatment.

BV-4051 oral formulation reduces IL-6 and TNF-alpha levels, stabilizing clotting factors to prevent thromboembolic events.